Crossmark

The clinical efficacy of PSMA PET/MRI in biochemically recurrent prostate cancer compared with standard of care imaging modalities and confirmatory histopathology: results of a single-centre, prospective clinical trial

Crossref DOI link: https://doi.org/10.1007/s10585-020-10043-1

Published Online: 2020-06-09

Published Print: 2020-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Joshi, A.

Roberts, M. J.

Perera, M.

Williams, E.

Rhee, H.

Pryor, D.

Lehman, M.

Heathcote, P.

Wood, S.

Coucher, J.

Gustafson, S.

Miles, K.

Vela, I.
Funding

Funding for this research was provided by:

PA Research Foundation

Prostate Cancer Foundation of Australia
License Information

Text and Data Mining valid from 2020-06-09

Version of Record valid from 2020-06-09
More Information

Article History

Received: 2 April 2020

Accepted: 5 June 2020

First Online: 9 June 2020

Compliance with ethical standards

:

: The authors have no conflict of interests.

Document is current

Any future updates will be listed below